Loading...
Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
As a new-generation CDK inhibitor, a CDK4/6 inhibitor combined with endocrine therapy has been successful in the treatment of advanced estrogen receptor–positive (ER+) breast cancer. Although there has been overall progress in the treatment of cancer, drug resistance is an emerging cause for breast...
Na minha lista:
| Udgivet i: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7751736/ https://ncbi.nlm.nih.gov/pubmed/33364954 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.580251 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|